Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1992-08-14
1993-10-19
Shah, Mukund J.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
544123, 544243, 544296, 544319, A61K 31505, C07D23922
Patent
active
052545580
ABSTRACT:
The present invention relates to certain novel substituted heterocycles which are 1-pyrimidinylacetamide compounds of formula I, set out herein, which are inhibitors of human leukocyte elastase (HLE), also known as human neutrophil elastase (HNE), making them useful whenever such inhibition is desired, such as for research tools in pharmacological, diagnostic and related studies and in the treatment of diseases in mammals in which HLE is implicated. The invention also includes intermediates useful in the synthesis of these substituted heterocycles, processes for preparing the substituted heterocycles, pharmaceutical compositions containing such substituted heterocycles and methods for their use.
REFERENCES:
patent: 4910190 (1990-03-01), Bergeson et al.
Bernstein Peter R.
Edwards Philip D.
Thomas Royston M.
Veale Chris A.
Warner Peter
Gupta Y. N.
Imperial Chemical Industries plc
Jackson Thomas E.
Shah Mukund J.
LandOfFree
Substituted 1,3-diazines as leukocyte elastase inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted 1,3-diazines as leukocyte elastase inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted 1,3-diazines as leukocyte elastase inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1351943